Evidence map›Paper›PMID 38871846›Full record

ArticleScientific reports2024

Association of myosteatosis with short-term outcomes in patients with acute-on-chronic liver failure.

Nan Geng, Ming Kong, Jiateng Zhang, Huina Chen, Manman Xu, Wenyan Song, Yu Chen, Zhongping Duan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. [Guidelines for the diagnosis and treatment of acute-on-chronic liver failure (2025 version)].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2025
    Guideline
  3. Pooled it
  4. Trial
  5. Review
  6. Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Nan Geng *Department of Infectious Diseases, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, 210008, China.
Ming Kong *Fourth Department of Liver Disease, Beijing Youan Hospital, Capital Medical University, NO.8 Xitou Tiao Road Youwai Street, Beijing, 100069, China.
Jiateng Zhang *Fourth Department of Liver Disease, Beijing Youan Hospital, Capital Medical University, NO.8 Xitou Tiao Road Youwai Street, Beijing, 100069, China.
Huina ChenBeijing Tiantan Hospital, Capital Medical University, Beijing, 100070, China.
Manman XuFourth Department of Liver Disease, Beijing Youan Hospital, Capital Medical University, NO.8 Xitou Tiao Road Youwai Street, Beijing, 100069, China.
Wenyan SongDepartment of Radiology, Beijing Youan Hospital, Capital Medical University, NO.8 Xitou Tiao Road Youwai Street, Beijing, 100069, China.
Yu ChenFourth Department of Liver Disease, Beijing Youan Hospital, Capital Medical University, NO.8 Xitou Tiao Road Youwai Street, Beijing, 100069, China. chybeyond1071@ccmu.edu.cn.
Zhongping DuanFourth Department of Liver Disease, Beijing Youan Hospital, Capital Medical University, NO.8 Xitou Tiao Road Youwai Street, Beijing, 100069, China. duan@ccmu.edu.cn.

Funding

Beijing Hospitals Authority's Ascent Plan DFL20221501Beijing Municipal Natural Science Foundation 7222094Construction Project of High-level Technology Talents in Public Health Discipline leader -01-12the Capital's Funds for Health Improvement and Research, China 2020-1-5031
6 · The paper itself

Abstract

Sarcopenia (low muscle mass, i.e., quantity) is associated with poor clinical outcomes in patients with acute-on-chronic liver failure (ACLF). In this study, we aimed to illustrate the clinical prognostic value of myosteatosis (muscle fat infiltration) for short-term mortality in patients with ACLF. We retrospectively enrolled consecutive patients with ACLF between January 2019 and January 2022. Computed tomography-based body composition analysis was performed at the third lumbar vertebral level to determine skeletal muscle radiation attenuation. Fine and Gray's competing risk regression model, with liver transplantation as a competing risk, was used to assess the factors associated with 90-day mortality. A total of 431 patients with ACLF were included. Myosteatosis and sarcopenia were observed in 261 (60.6%) and 87 (20.2%) patients, respectively. Competitive risk regression showed that age (HR 1.021, 95% CI 1.000-1.043, P = 0.042), APASL ACLF Research Consortium (AARC) score (HR 1.498, 95% CI 1.312-1.710, P < 0.001), and sarcopenia (HR 1.802, 95% CI 1.062-3.060, P = 0.029) were independently associated with increased 90-day mortality. Subgroup analysis of male patients with HBV-ACLF revealed that myosteatosis (HR 2.119, 95% CI 1.101-4.078, P = 0.025) was promising prognostic factors for 90-day mortality after being adjusted for ascites, acute kidney injury, AARC score, and sarcopenia. Myosteatosis is predictive of short-term outcomes in male patients with HBV-ACLF. Our results emphasise the importance of focusing on muscle fat infiltration in patients with HBV-ACLF. Further studies are warranted to investigate the underlying mechanisms and potential therapies for myosteatosis.

Indexed as

Acute-On-Chronic Liver FailureSarcopeniaAdipose TissueAdultAgedBody CompositionFemaleHumansMaleMiddle AgedMuscle, SkeletalPrognosisRetrospective StudiesRisk FactorsTomography, X-Ray ComputedAcute on chronic liver failureAPASL ACLF Research ConsortiumMuscle qualitySarcopeniaSkeletal muscle radiation attenuation

Identifiers

PMID38871846
PMCPMC11176162

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.